Define the portfolio and review scope
Agree the product population, decision requirements, permissions, and operational handoff.
Build a consistent evidence foundation across the portfolios your institution manages. Bring underwriting, monitoring, and review into a connected workflow while retaining your policies and governance.
Explore your segment
Choose a segment to explore the evidence, financial relationships, and changes that matter to the review. The analytical scope follows the product and the information your institution is permitted to use.
Support consumer and commercial assessments with a consistent evidence model while preserving product-specific definitions. Review related exposure, exceptions, and the assumptions behind findings without conflating institution-level reporting with borrower-level risk.
Concentration, financial change, and unresolved evidence by portfolio segment.

Agree the product population, decision requirements, permissions, and operational handoff.
Review supported outputs, missingness, and analyst corrections using your institution’s assessment criteria.
Deliver findings to authorized systems with clear accountability for decisions and intervention.
Bring the agreed evidence snapshot, supported calculations, and findings into a reviewable underwriting context.
Explore underwritingMonitor existing relationships and reassess permitted new evidence against the baseline, with source limitations visible.
Explore monitoringExplore the detailed guides for Canada and the United States, including dated market context, assessment methods, implementation considerations, and source references.
Agree the evidence sources, jurisdiction, product definitions, and decision responsibilities before implementation. Test missing information and exceptions as carefully as completed assessments.
Amlok supports the intelligence workflow. Your institution retains its policy, system of record, credit decisions, and operational actions.
Use representative, authorized product cohorts and comparable evidence windows. Measure evidence quality, review needs, and operational outcomes separately; aggregate market statistics are not model accuracy results.
Public market observations provide context, not an Amlok performance claim or a universal approval threshold. Preserve geography, reporting period, product population, and denominator when comparing results. Page illustrations are fictional.
A point-in-time decision does not need to become a blind spot for the life of the deal.
